Bayer and Dimension strike a $252 million deal

Dimension Therapeutics and Bayer HealthCare Enter Collaboration to Develop Novel Gene Therapy for Hemophilia A
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CAMBRIDGE, Mass.—Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, announced recently that it has entered into a collaboration with Germany-based Bayer HealthCare for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.
 
Under the terms of the agreement, Dimension will receive an upfront payment of $20 million and will be eligible for potential development and commercialization milestone payments of as much as $232 million. Dimension will be responsible for all preclinical development activities and the Phase 1/2a clinical trial, with funding from Bayer. Depending on the results of the Phase 1/2a clinical trial, Bayer would conduct the confirmatory Phase 3 trial, make all regulatory submissions and would have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Dimension is eligible to receive tiered royalties based on product sales.
 
“Currently available replacement therapies for hemophilia A are often administered intravenously multiple times a week and may be required for life, depending on the severity of a patient’s disease,” said Dr. Thomas R. Beck, CEO of Dimension Therapeutics. “Gene therapy offers the potential to transform the treatment of hemophilia by inserting a correct version of the faulty gene responsible for the disease. We are proud to partner with Bayer, a leader in the treatment of hemophilia A, to develop a therapy with the potential to significantly change the treatment landscape.”
 
“Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for patients with hemophilia A,” said Dr. Andreas Busch, member of the Bayer HealthCare executive committee and head of global drug discovery. “We are excited to partner with Dimension Therapeutics to jointly harness the power of gene therapy to drive the development of new long-term options in treating this disease.”
 
Hemophilia is a rare bleeding disorder in which patients produce little or no clotting factor, a protein needed for normal blood clotting, which can cause life threatening bleeding. Hemophilia A is the most common type of hemophilia in the United States, with approximately one in 5,000 males born with the condition1.
 
Dimension’s AAV vector technology allows for systemic intravenous administration of the clotting factor gene in vivo, which has been shown in preclinical studies to target the liver, which is intended to result in long-lasting expression of FVIII protein at therapeutic levels.
 
Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Formed in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its AAV therapeutic capabilities and advancing multiple gene therapy programs in rare diseases, and is advancing a wholly-owned hemophilia B program toward clinical development.
 
SOURCE: Dimension Therapeutics news release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue